|
CA1271477A
(en)
|
1983-11-18 |
1990-07-10 |
John F. Gerster |
1h-imidazo[4,5-c]quinolin-4-amines
|
|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
|
US5567610A
(en)
|
1986-09-04 |
1996-10-22 |
Bioinvent International Ab |
Method of producing human monoclonal antibodies and kit therefor
|
|
IL106992A
(en)
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Acylhydrazone derivatives of anthracycline and methods for their preparation
|
|
FI903489A0
(fi)
|
1988-11-11 |
1990-07-10 |
Medical Res Council |
Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US6399754B1
(en)
|
1991-12-24 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides
|
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
|
US5229275A
(en)
|
1990-04-26 |
1993-07-20 |
Akzo N.V. |
In-vitro method for producing antigen-specific human monoclonal antibodies
|
|
US6280932B1
(en)
|
1990-06-11 |
2001-08-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands to lectins
|
|
US5853984A
(en)
|
1990-06-11 |
1998-12-29 |
Nexstar Pharmaceuticals, Inc. |
Use of nucleic acid ligands in flow cytometry
|
|
US5567588A
(en)
|
1990-06-11 |
1996-10-22 |
University Research Corporation |
Systematic evolution of ligands by exponential enrichment: Solution SELEX
|
|
US5270163A
(en)
|
1990-06-11 |
1993-12-14 |
University Research Corporation |
Methods for identifying nucleic acid ligands
|
|
US6716580B2
(en)
|
1990-06-11 |
2004-04-06 |
Somalogic, Inc. |
Method for the automated generation of nucleic acid ligands
|
|
US5763177A
(en)
|
1990-06-11 |
1998-06-09 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
|
|
US5660985A
(en)
|
1990-06-11 |
1997-08-26 |
Nexstar Pharmaceuticals, Inc. |
High affinity nucleic acid ligands containing modified nucleotides
|
|
CA2084987C
(en)
|
1990-06-11 |
2007-02-13 |
Gilead Sciences, Inc. |
Nucleic acid ligands
|
|
US5496938A
(en)
|
1990-06-11 |
1996-03-05 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligands to HIV-RT and HIV-1 rev
|
|
US5874218A
(en)
|
1990-06-11 |
1999-02-23 |
Nexstar Pharmaceuticals, Inc. |
Method for detecting a target compound in a substance using a nucleic acid ligand
|
|
US6465189B1
(en)
|
1990-06-11 |
2002-10-15 |
Gilead Sciences, Inc. |
Systematic evolution of ligands by exponential enrichment: blended selex
|
|
US6001577A
(en)
|
1998-06-08 |
1999-12-14 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
|
|
US5789163A
(en)
|
1990-06-11 |
1998-08-04 |
Nexstar Pharmaceuticals, Inc. |
Enzyme linked oligonucleotide assays (ELONAS)
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
US5226575A
(en)
|
1991-11-21 |
1993-07-13 |
Scott Faust |
Pneumatic mortar dispenser with flex release
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
DE69333807T2
(de)
|
1992-02-06 |
2006-02-02 |
Chiron Corp., Emeryville |
Marker für krebs und biosynthetisches bindeprotein dafür
|
|
US6608201B2
(en)
|
1992-08-28 |
2003-08-19 |
3M Innovative Properties Company |
Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US5352784A
(en)
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
|
US6458539B1
(en)
|
1993-09-17 |
2002-10-01 |
Somalogic, Inc. |
Photoselection of nucleic acid ligands
|
|
US5798340A
(en)
|
1993-09-17 |
1998-08-25 |
Gilead Sciences, Inc. |
Nucleotide analogs
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5482936A
(en)
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5843732A
(en)
|
1995-06-06 |
1998-12-01 |
Nexstar Pharmaceuticals, Inc. |
Method and apparatus for determining consensus secondary structures for nucleic acid sequences
|
|
ATE234635T1
(de)
|
1995-12-22 |
2003-04-15 |
Bristol Myers Squibb Co |
Verzweigte hydrazongruppen enthaltende kuppler
|
|
US5922695A
(en)
|
1996-07-26 |
1999-07-13 |
Gilead Sciences, Inc. |
Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
|
|
WO1998008856A2
(de)
|
1996-08-30 |
1998-03-05 |
Fuerste Jens Peter |
Spiegelselektion und spiegelevolution von nucleinsäuren
|
|
US6127533A
(en)
|
1997-02-14 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
2'-O-aminooxy-modified oligonucleotides
|
|
UA67760C2
(uk)
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
|
|
US6242246B1
(en)
|
1997-12-15 |
2001-06-05 |
Somalogic, Inc. |
Nucleic acid ligand diagnostic Biochip
|
|
US6110929A
(en)
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
|
US6403779B1
(en)
|
1999-01-08 |
2002-06-11 |
Isis Pharmaceuticals, Inc. |
Regioselective synthesis of 2′-O-modified nucleosides
|
|
US20030054360A1
(en)
|
1999-01-19 |
2003-03-20 |
Larry Gold |
Method and apparatus for the automated generation of nucleic acid ligands
|
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
|
US6331539B1
(en)
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
|
ES2466715T3
(es)
|
1999-06-25 |
2014-06-11 |
Immunogen, Inc. |
Métodos de tratamiento usando conjugados de anticuerpo anti-ErbB-maitansinoide
|
|
US6506887B1
(en)
|
1999-07-29 |
2003-01-14 |
Somalogic, Incorporated |
Conditional-selex
|
|
US6635677B2
(en)
|
1999-08-13 |
2003-10-21 |
Case Western Reserve University |
Methoxyamine combinations in the treatment of cancer
|
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
|
US20050020525A1
(en)
|
2002-02-20 |
2005-01-27 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US20050032733A1
(en)
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
DE20014503U1
(de)
|
2000-08-22 |
2001-01-11 |
Siemens AG, 80333 München |
Fertigungsstraßenabschnitt
|
|
US6376190B1
(en)
|
2000-09-22 |
2002-04-23 |
Somalogic, Inc. |
Modified SELEX processes without purified protein
|
|
UA74593C2
(en)
|
2000-12-08 |
2006-01-16 |
3M Innovative Properties Co |
Substituted imidazopyridines
|
|
US20060057651A1
(en)
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
US6664264B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
|
AU2006216669A1
(en)
*
|
2000-12-08 |
2006-08-31 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
|
UA74852C2
(en)
|
2000-12-08 |
2006-02-15 |
3M Innovative Properties Co |
Urea-substituted imidazoquinoline ethers
|
|
US20030175950A1
(en)
|
2001-05-29 |
2003-09-18 |
Mcswiggen James A. |
RNA interference mediated inhibition of HIV gene expression using short interfering RNA
|
|
DK1264603T3
(da)
|
2001-06-10 |
2010-04-26 |
Noxxon Pharma Ag |
Anvendelse af L-polynukleotider til in vivo-billeddannelse
|
|
AU2775402A
(en)
|
2001-06-29 |
2003-01-02 |
Medimolecular Pty Ltd |
Nucleic acid ligands to complex targets
|
|
US20030139364A1
(en)
|
2001-10-12 |
2003-07-24 |
University Of Iowa Research Foundation |
Methods and products for enhancing immune responses using imidazoquinoline compounds
|
|
US20040014779A1
(en)
|
2001-11-16 |
2004-01-22 |
3M Innovative Properties Company |
Methods and compositions related to IRM compounds and toll-like recptor pathways
|
|
KR100718371B1
(ko)
|
2001-11-27 |
2007-05-14 |
애나디스 파마슈티칼스, 인코포레이티드 |
３-β-Ｄ-리보푸라노실티아졸로[４,５-ｄ]피리디민누클레오시드 및 이의 용도
|
|
WO2003057145A2
(en)
|
2001-12-31 |
2003-07-17 |
Guilford Pharmaceuticals Inc. |
SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
AU2003276131A1
(en)
|
2002-06-18 |
2003-12-31 |
Epigenesis Pharmaceuticals, Inc. |
A dry powder oligonucleotide formulation, preparation and its uses
|
|
EP2206517B1
(en)
|
2002-07-03 |
2023-08-02 |
Ono Pharmaceutical Co., Ltd. |
Immunopotentiating compositions comprising anti-PD-L1 antibodies
|
|
DK1545613T3
(da)
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
|
EP1413316A1
(en)
|
2002-09-27 |
2004-04-28 |
Bruno Robert |
Bifunctional conjugates or fusion proteins
|
|
CA2510375A1
(en)
|
2002-12-20 |
2004-07-15 |
3M Innovative Properties Company |
Aryl / hetaryl substituted imidazoquinolines
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
MXPA05007466A
(es)
|
2003-01-09 |
2006-03-08 |
Arizeke Pharmaceuticals Inc |
Metodos para el tratamiento de enfermedades pulmonares.
|
|
US9259459B2
(en)
|
2003-01-31 |
2016-02-16 |
Celldex Therapeutics Inc. |
Antibody vaccine conjugates and uses therefor
|
|
JP2006517974A
(ja)
|
2003-02-13 |
2006-08-03 |
スリーエム イノベイティブ プロパティズ カンパニー |
Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
|
|
ATE472338T1
(de)
|
2003-02-20 |
2010-07-15 |
Seattle Genetics Inc |
Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
|
|
ES2342069T4
(es)
|
2003-09-05 |
2011-01-26 |
Anadys Pharmaceuticals, Inc. |
Ligandos de tlr7 para el tratamiento de la hepatitis c.
|
|
NZ546274A
(en)
|
2003-10-03 |
2009-12-24 |
3M Innovative Properties Co |
Pyrazolopyridines and analags thereof
|
|
RU2426734C2
(ru)
|
2003-10-03 |
2011-08-20 |
Зм Инновейтив Пропертиз Компани |
Пиразолопиридины и их аналоги
|
|
AR046046A1
(es)
|
2003-10-03 |
2005-11-23 |
3M Innovative Properties Co |
Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
|
|
WO2005034979A2
(en)
|
2003-10-11 |
2005-04-21 |
Inex Pharmaceuticals Corporation |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
|
ITMI20032121A1
(it)
|
2003-11-04 |
2005-05-05 |
Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm |
Procedimento per la preparazione di imiquimod e suoi intermedi
|
|
CN107213469A
(zh)
*
|
2003-11-06 |
2017-09-29 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
|
WO2005067500A2
(en)
|
2003-12-30 |
2005-07-28 |
3M Innovative Properties Company |
Enhancement of immune responses
|
|
TWI392678B
(zh)
|
2004-03-26 |
2013-04-11 |
Dainippon Sumitomo Pharma Co |
９-取代-８-氧基腺嘌呤化合物
|
|
EP1776105A2
(en)
|
2004-07-18 |
2007-04-25 |
Coley Pharmaceutical Group, Ltd |
Methods and compositions for inducing innate immune responses
|
|
KR101270829B1
(ko)
*
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
|
US20060135459A1
(en)
|
2004-11-09 |
2006-06-22 |
Epstein Alan L |
Targeted innate immunity
|
|
PT1830876E
(pt)
*
|
2004-12-30 |
2015-07-13 |
Meda Ab |
Utilização de imiquimod para o tratamento de metástases cutâneas derivadas de um tumor cancerígeno da mama
|
|
CN101128431B
(zh)
|
2005-02-24 |
2011-05-25 |
詹森药业有限公司 |
作为钾离子通道打开剂的喹啉衍生物
|
|
KR20080003422A
(ko)
|
2005-04-14 |
2008-01-07 |
메르크 파텐트 게엠베하 |
종양 조직 내의 ｅｇｆｒ 유전자의 증가된 복제수에 기초한항-ｅｇｆｒ 항체 치료
|
|
CN101203241B
(zh)
|
2005-04-19 |
2012-02-22 |
西雅图基因公司 |
人源化抗-cd70结合物和其应用
|
|
US7976852B2
(en)
|
2005-04-26 |
2011-07-12 |
Eisai R&D Management Co., Ltd. |
Compositions and methods for cancer immunotherapy
|
|
KR101418367B1
(ko)
|
2005-05-04 |
2014-07-25 |
녹손 파르마 아게 |
에이치엠지에이-결합 핵산
|
|
ES2720160T3
(es)
*
|
2005-05-09 |
2019-07-18 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
|
|
EA019344B1
(ru)
|
2005-07-01 |
2014-03-31 |
МЕДАРЕКС, Эл.Эл.Си. |
Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
|
|
US8871720B2
(en)
|
2005-07-07 |
2014-10-28 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
|
|
TW201402124A
(zh)
|
2005-08-19 |
2014-01-16 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
|
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
|
|
AU2006287416A1
(en)
|
2005-09-07 |
2007-03-15 |
Medimmune, Llc |
Toxin conjugated Eph receptor antibodies
|
|
ZA200803029B
(en)
|
2005-09-09 |
2009-02-25 |
Coley Pharm Group Inc |
Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
|
|
EP1940470B1
(en)
*
|
2005-09-26 |
2013-04-17 |
Medarex, Inc. |
Antibody-drug conjugates and their use
|
|
EP1988896A4
(en)
|
2006-02-22 |
2011-07-27 |
3M Innovative Properties Co |
CONJUGATES TO MODIFY IMMUNE REACTIONS
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
US20080031887A1
(en)
|
2006-06-30 |
2008-02-07 |
Joseph Lustgarten |
Conjugates for inducing targeted immune responses and methods of making and using same
|
|
US8138172B2
(en)
|
2006-07-05 |
2012-03-20 |
Astrazeneca Ab |
8-oxoadenine derivatives acting as modulators of TLR7
|
|
EP2061814B1
(en)
|
2006-10-27 |
2012-06-06 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
|
JP5405311B2
(ja)
|
2006-12-21 |
2014-02-05 |
エフ．ホフマン−ラ ロシュ アーゲー |
ｍＧｌｕＲ５受容体アンタゴニストの多形
|
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
TWI422594B
(zh)
|
2007-02-02 |
2014-01-11 |
Baylor Res Inst |
經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
|
|
ES2552471T3
(es)
|
2007-02-07 |
2015-11-30 |
The Regents Of The University Of California |
Conjugados de agonistas de TLR sintéticos y usos de los mismos
|
|
JP5394246B2
(ja)
*
|
2007-03-30 |
2014-01-22 |
ジェネンテック， インコーポレイテッド |
抗体及びイムノコンジュゲートとこれらの使用方法
|
|
AU2008247165B2
(en)
|
2007-05-08 |
2011-11-03 |
Astrazeneca Ab |
Imidazoquinolines with immuno-modulating properties
|
|
WO2009018500A1
(en)
|
2007-07-31 |
2009-02-05 |
The Johns Hopkins University |
Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
|
|
CA3128656A1
(en)
|
2007-08-22 |
2009-02-26 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
|
JP5410434B2
(ja)
|
2007-09-28 |
2014-02-05 |
バインド セラピューティックス インコーポレイテッド |
ナノ粒子を用いた癌細胞の標的化
|
|
AU2008347400B2
(en)
|
2008-01-15 |
2014-12-11 |
Meda Ab |
Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives
|
|
US9358307B2
(en)
|
2008-01-25 |
2016-06-07 |
Gavish-Galilee Bio Applications Ltd. |
Targeting of innate immune response to tumor site
|
|
EP2259788A4
(en)
|
2008-02-07 |
2011-03-16 |
Univ California |
TREATMENT OF BLADDER DISEASES WITH A TLR7 ACTIVATOR
|
|
HUE035184T2
(en)
|
2008-03-18 |
2018-05-02 |
Genentech Inc |
Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
|
|
US8772243B2
(en)
|
2008-08-20 |
2014-07-08 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for predicting the response to anti-cancer treatment with an agonist of TLR7 or an agonist of TLR8
|
|
BRPI0919377A2
(pt)
|
2008-09-26 |
2016-09-27 |
Dana Farber Cancer Inst Inc |
anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
|
|
US8895702B2
(en)
|
2008-12-08 |
2014-11-25 |
City Of Hope |
Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
|
|
WO2010077613A1
(en)
|
2008-12-09 |
2010-07-08 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
WO2010129895A2
(en)
|
2009-05-07 |
2010-11-11 |
Immunocellular Therapeutics, Ltd. |
Cd133 epitopes
|
|
WO2010132622A2
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of California |
Anticd20-cpg conjugates and methods of treating b cell malignancies
|
|
US20110077263A1
(en)
|
2009-09-29 |
2011-03-31 |
University Of Southern California |
Methods and Compositions of Toll-Like Receptor (TLR) Agonists
|
|
PT2504364T
(pt)
|
2009-11-24 |
2017-11-14 |
Medimmune Ltd |
Agentes de ligação direcionados contra b7-h1
|
|
WO2011084726A1
(en)
|
2009-12-21 |
2011-07-14 |
3M Innovative Properties Company |
BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
|
|
WO2011084725A1
(en)
|
2009-12-21 |
2011-07-14 |
3M Innovative Properties Company |
4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
|
|
MX339621B
(es)
|
2010-04-13 |
2016-06-02 |
Celldex Therapeutics Inc * |
Anticuerpos que se unen a cd27 humano y uso de los mismos.
|
|
WO2011150258A1
(en)
|
2010-05-26 |
2011-12-01 |
Selecta Biosciences, Inc. |
Dose selection of adjuvanted synthetic nanocarriers
|
|
TWI506035B
(zh)
|
2010-08-13 |
2015-11-01 |
Baylor Res Inst |
以直接針對抗原呈現細胞之抗體的標靶佐劑為主之新穎疫苗佐劑
|
|
CN107970451A
(zh)
|
2010-10-01 |
2018-05-01 |
帆德制药股份有限公司 |
Tlr激动剂和联合治疗的治疗应用
|
|
MX2013006392A
(es)
*
|
2010-12-09 |
2013-12-06 |
Genentech Inc |
Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
|
|
WO2012097177A2
(en)
|
2011-01-12 |
2012-07-19 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
|
ES2700514T3
(es)
|
2011-02-01 |
2019-02-18 |
Genmab As |
Anticuerpos humanos y conjugados de anticuerpo-fármaco contra CD74
|
|
US20120231023A1
(en)
|
2011-03-08 |
2012-09-13 |
Baylor Research Institute |
Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
KR101649610B1
(ko)
|
2011-04-21 |
2016-08-19 |
오리제니스 게엠베하 |
키나아제 억제제로서의 헤테로사이클릭 화합물
|
|
UY34032A
(es)
|
2011-04-21 |
2012-11-30 |
Origenis Gmbh |
Nuevos inhibidores de quinasa
|
|
US8728486B2
(en)
|
2011-05-18 |
2014-05-20 |
University Of Kansas |
Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
|
|
JP6240600B2
(ja)
|
2011-07-24 |
2017-11-29 |
キュアテク リミテッド |
ヒト化免疫モノクローナル抗体の変異体
|
|
EA026924B1
(ru)
|
2011-08-01 |
2017-05-31 |
Дженентек, Инк. |
Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
|
|
JP6046716B2
(ja)
|
2011-08-11 |
2016-12-21 |
ハンツマン・アドバンスド・マテリアルズ・アメリカズ・エルエルシー |
ベンゾオキサジン化合物の生産方法
|
|
CN103957939A
(zh)
|
2011-09-19 |
2014-07-30 |
约翰霍普金斯大学 |
癌症免疫治疗
|
|
US9474689B2
(en)
|
2011-10-25 |
2016-10-25 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
JP2014532799A
(ja)
|
2011-11-09 |
2014-12-08 |
アセンド・バイオファーマシューティカルズ・リミテッド |
免疫調節結合体
|
|
US9556167B2
(en)
*
|
2012-05-02 |
2017-01-31 |
Yale University |
TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
|
|
US9212224B2
(en)
|
2012-05-15 |
2015-12-15 |
Bristol-Myers Squibb Company |
Antibodies that bind PD-L1 and uses thereof
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
CN104936982B
(zh)
|
2012-08-03 |
2020-04-24 |
丹娜法伯癌症研究院 |
抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
|
|
TR201900694T4
(tr)
|
2012-08-23 |
2019-02-21 |
Agensys Inc |
158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc).
|
|
US9637491B2
(en)
|
2012-10-19 |
2017-05-02 |
Origenis Gmbh |
Pyrazolo[4,3-D]pyrimidines as kinase inhibitors
|
|
US10000482B2
(en)
|
2012-10-19 |
2018-06-19 |
Origenis Gmbh |
Kinase inhibitors
|
|
EP2787005A1
(en)
|
2013-04-02 |
2014-10-08 |
Activartis Biotech GmbH |
Targeted cancer immune therapy
|
|
JP7060324B2
(ja)
|
2013-12-20 |
2022-04-26 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ネオ抗原ワクチンによる併用療法
|
|
AU2015205753A1
(en)
|
2014-01-10 |
2016-07-21 |
Birdie Biopharmaceuticals Inc. |
Compounds and compositions for treating HER2 positive tumors
|
|
US20150374815A1
(en)
|
2014-06-25 |
2015-12-31 |
Selecta Biosciences, Inc. |
Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
|
|
WO2016004876A1
(en)
|
2014-07-09 |
2016-01-14 |
Shanghai Birdie Biotech, Inc. |
Anti-pd-l1 combinations for treating tumors
|
|
CN112546230A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
CN105732635A
(zh)
|
2014-12-29 |
2016-07-06 |
南京明德新药研发股份有限公司 |
一类Toll样受体7激动剂
|
|
DK3345907T3
(da)
|
2015-09-01 |
2020-06-22 |
Taiho Pharmaceutical Co Ltd |
Pyrazolo[3,4-d]pyrimidinforbindelser eller salte deraf
|
|
US10821127B2
(en)
|
2015-11-09 |
2020-11-03 |
Shaperon Inc. |
Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient
|
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN118515666A
(zh)
|
2017-04-27 |
2024-08-20 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
KR20200019226A
(ko)
|
2017-06-23 |
2020-02-21 |
버디 바이오파마슈티칼즈, 인크. |
약학 조성물
|
|
CN113164460A
(zh)
|
2018-09-07 |
2021-07-23 |
博笛生物科技有限公司 |
咪唑喹啉化合物及其应用
|
|
JP2022516093A
(ja)
|
2018-12-26 |
2022-02-24 |
バーディー バイオファーマシューティカルズ インコーポレイテッド |
癌の治療のための免疫調節薬の組み合わせおよび方法
|
|
JP2022525216A
(ja)
|
2019-03-15 |
2022-05-11 |
バーディー バイオファーマシューティカルズ インコーポレイテッド |
癌の治療のための免疫調節組成物および方法
|
|
JP2023539625A
(ja)
|
2020-08-26 |
2023-09-15 |
バーディー バイオファーマシューティカルズ インコーポレイテッド |
Ｔｌｒアゴニストによるがんの処置
|